Cargando…

Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial

BACKGROUND: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) reduce glucose levels, body weight, and blood pressure, possibly resulting in cardiovascular protection. In phase III trials, SGLT2i were shown to increase HDL cholesterol. We aimed to evaluate whether the SGLT2i dapagliflozin affects H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fadini, Gian Paolo, Bonora, Benedetta Maria, Zatti, Giancarlo, Vitturi, Nicola, Iori, Elisabetta, Marescotti, Maria Cristina, Albiero, Mattia, Avogaro, Angelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379610/ https://www.ncbi.nlm.nih.gov/pubmed/28376855 http://dx.doi.org/10.1186/s12933-017-0529-3

Ejemplares similares

Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
por: Bonora, Benedetta Maria, et al.
Publicado: (2019)

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
por: Bonora, Benedetta Maria, et al.
Publicado: (2021)

DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes
por: Fadini, Gian Paolo, et al.
Publicado: (2017)

Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Nascent HDL (High-Density Lipoprotein) Discs Carry Cholesterol to HDL Spheres: Effects of HDL Particle Remodeling on Cholesterol Efflux
por: Navdaev, Alexei V., et al.
Publicado: (2020)

Uremia alters HDL composition and cholesterol efflux capacity
por: Holzer, Michael, et al.
Publicado: (2012)

p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complications
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity
por: Luo, Mengdie, et al.
Publicado: (2017)

Human paraoxonase 1 overexpression in mice stimulates HDL cholesterol efflux and reverse cholesterol transport
por: Ikhlef, Souade, et al.
Publicado: (2017)

HDL Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus
por: García-González, María, et al.
Publicado: (2023)

Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity
por: Rubinow, Katya B., et al.
Publicado: (2012)

HDL Cholesterol Efflux and Serum Cholesterol Loading Capacity Alterations Associate to Macrophage Cholesterol Accumulation in FH Patients with Achilles Tendon Xanthoma
por: Adorni, Maria Pia, et al.
Publicado: (2022)

Lack of Correlation of Plasma HDL With Fecal Cholesterol and Plasma Cholesterol Efflux Capacity Suggests Importance of HDL Functionality in Attenuation of Atherosclerosis
por: Srivastava, Neelam, et al.
Publicado: (2018)

Impaired HDL2-mediated cholesterol efflux is associated with metabolic syndrome in families with early onset coronary heart disease and low HDL-cholesterol level
por: Paavola, Timo, et al.
Publicado: (2017)

The negative effect of ANGPTL8 on HDL-mediated cholesterol efflux capacity
por: Luo, Mengdie, et al.
Publicado: (2018)

9-cis β-Carotene Increased Cholesterol Efflux to HDL in Macrophages
por: Bechor, Sapir, et al.
Publicado: (2016)

Cholesterol Efflux Efficiency of Reconstituted HDL Is Affected by Nanoparticle Lipid Composition
por: Jebari-Benslaiman, Shifa, et al.
Publicado: (2020)

Lower than average HDL cholesterol efflux capacity in Lithuanian population
por: Kutkiene, Sandra, et al.
Publicado: (2019)

HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis
por: Ferraz-Amaro, Iván, et al.
Publicado: (2021)

Effects of pre-eclampsia on HDL-mediated cholesterol efflux capacity after pregnancy
por: Kockx, Maaike, et al.
Publicado: (2022)

Response to Chia Siang Kow and colleagues
por: Avogaro, Angelo, et al.
Publicado: (2022)

Normal HDL Cholesterol Efflux and Anti-Inflammatory Capacities in Type 2 Diabetes Despite Lipidomic Abnormalities
por: Denimal, Damien, et al.
Publicado: (2022)

Inclusion of Almonds in a Cholesterol-Lowering Diet Improves Plasma HDL Subspecies and Cholesterol Efflux to Serum in Normal-Weight Individuals with Elevated LDL Cholesterol
por: Berryman, Claire E, et al.
Publicado: (2017)

Managing diabetes in diabetic patients with COVID: where do we start from?
por: Avogaro, Angelo, et al.
Publicado: (2021)

In Vivo Inflammation Does Not Impair ABCA1-Mediated Cholesterol Efflux Capacity of HDL
por: Franssen, Remco, et al.
Publicado: (2012)

Extra Virgin Olive Oil Polyphenols Promote Cholesterol Efflux and Improve HDL Functionality
por: Berrougui, Hicham, et al.
Publicado: (2015)

Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis
por: Zhou, Mei, et al.
Publicado: (2019)

A meta-analysis of HDL cholesterol efflux capacity and concentration in patients with rheumatoid arthritis
por: Xie, Binbin, et al.
Publicado: (2021)

The association between impairment of HDL cholesterol efflux capacity and atrial remodeling in atrial fibrillation
por: Minami-Takano, Asuka, et al.
Publicado: (2021)

Low HDL Cholesterol Efflux Capacity Indicates a Fatal Course of COVID-19
por: Stadler, Julia T., et al.
Publicado: (2022)

HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis
por: Tejera-Segura, Beatriz, et al.
Publicado: (2017)

Glycaemic Control Among People with Type 1 Diabetes During Lockdown for the SARS-CoV-2 Outbreak in Italy
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Diabetes Impairs Stem Cell and Proangiogenic Cell Mobilization in Humans
por: Fadini, Gian Paolo, et al.
Publicado: (2013)

Targeted cholesterol efflux
por: Fang, Longhou, et al.
Publicado: (2013)

Higher non-HDL-cholesterol to HDL-cholesterol ratio linked with increased nonalcoholic steatohepatitis
por: Wang, Dianhui, et al.
Publicado: (2018)

The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients
por: Poncina, Nicol, et al.
Publicado: (2014)

Impaired HDL cholesterol efflux in metabolic syndrome is unrelated to glucose tolerance status: the CODAM study
por: Annema, Wijtske, et al.
Publicado: (2016)

Effect of Selective Androgen Receptor Modulator on Cholesterol Efflux Capacity, Size, and Subspecies of HDL Particles
por: Guo, Wen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eo1alqledfn0al83ietcnt5tta